{"id":70176,"date":"2026-07-17T21:43:37","date_gmt":"2026-07-17T13:43:37","guid":{"rendered":"https:\/\/flcube.com\/?p=70176"},"modified":"2026-07-17T21:43:38","modified_gmt":"2026-07-17T13:43:38","slug":"hengruis-hrs9531-dual-gipr-glp-1r-agonist-advances-to-phase-iii-for-obesity-with-knee-osteoarthritis-expanding-metabolic-disease-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70176","title":{"rendered":"Hengrui&#8217;s HRS9531 Dual GIPR\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that its <strong>HRS9531 injection<\/strong> has received approval from China&#8217;s National Medical Products Administration (NMPA) to conduct a Phase III clinical trial in adult patients with obesity complicated with knee osteoarthritis. HRS9531 is a novel dual agonist targeting both the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), representing a significant expansion of Hengrui&#8217;s metabolic disease pipeline.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>China National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HRS9531 injection<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Obesity complicated with knee osteoarthritis<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults with comorbid obesity and knee osteoarthritis<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Dual GIPR\/GLP-1R agonist<\/td><\/tr><tr><td><strong>Intellectual Property<\/strong><\/td><td>Globally independent IP rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Novel dual receptor agonist<\/li>\n\n\n\n<li><strong>Primary Targets:<\/strong> Gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R)<\/li>\n\n\n\n<li><strong>Metabolic Effects:<\/strong><\/li>\n\n\n\n<li>Regulates glucolipid metabolism<\/li>\n\n\n\n<li>Suppresses appetite through central nervous system pathways<\/li>\n\n\n\n<li>Enhances insulin sensitivity in peripheral tissues<\/li>\n\n\n\n<li><strong>Therapeutic Outcomes:<\/strong> Simultaneous improvements in blood glucose control and weight reduction<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Dual agonism may provide superior efficacy compared to selective GLP-1 receptor agonists<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pipeline-expansion-strategy\" class=\"wp-block-heading\">Pipeline Expansion Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Development Stage<\/th><th>Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>Obesity with Knee Osteoarthritis<\/strong><\/td><td>Phase III (new)<\/td><td>Addresses dual burden of metabolic and musculoskeletal disease<\/td><\/tr><tr><td><strong>Weight Management<\/strong><\/td><td>Clinical trials approved<\/td><td>Core metabolic indication leveraging weight loss efficacy<\/td><\/tr><tr><td><strong>Chronic Kidney Disease<\/strong><\/td><td>Clinical trials approved<\/td><td>Metabolic benefits may slow CKD progression<\/td><\/tr><tr><td><strong>Cardiovascular Disease<\/strong><\/td><td>Clinical trials approved<\/td><td>Cardiometabolic protection through multiple pathways<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-context\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity-Osteoarthritis Comorbidity:<\/strong> Affects approximately 28% of adults with knee osteoarthritis in China, representing 15+ million patients<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> No approved therapies specifically addressing both conditions simultaneously<\/li>\n\n\n\n<li><strong>GLP-1 Market Dynamics:<\/strong> Global GLP-1 agonist market projected to exceed $100 billion by 2030, with dual\/triple agonists commanding premium positioning<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Positions Hengrui alongside global leaders developing GIPR\/GLP-1R dual agonists including Novo Nordisk and Eli Lilly<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-implications\" class=\"wp-block-heading\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China-First Strategy:<\/strong> Leveraging domestic regulatory advantages while building global development plans<\/li>\n\n\n\n<li><strong>Manufacturing Scale:<\/strong> Existing biologics manufacturing capacity supports rapid scale-up upon approval<\/li>\n\n\n\n<li><strong>Pricing Potential:<\/strong> Premium pricing expected given dual mechanism and unmet need in comorbid population<\/li>\n\n\n\n<li><strong>Partnership Opportunities:<\/strong> Strong asset profile attractive for international licensing partnerships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market opportunities for HRS9531. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260717_RFAZ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260717_RFAZ.\"><\/object><a id=\"wp-block-file--media-5029b100-ba66-40ab-b430-3fd51249cc82\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260717_RFAZ.pdf\">600276_20260717_RFAZ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260717_RFAZ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5029b100-ba66-40ab-b430-3fd51249cc82\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,2586,4228,4361,86,852],"class_list":["post-70176","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-hot-targets","tag-obesity","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui&#039;s HRS9531 Dual GIPR\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has received approval from China&#039;s National Medical Products Administration (NMPA) to conduct a Phase III clinical trial in adult patients with obesity complicated with knee osteoarthritis. HRS9531 is a novel dual agonist targeting both the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), representing a significant expansion of Hengrui&#039;s metabolic disease pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70176\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui&#039;s HRS9531 Dual GIPR\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has received approval from China&#039;s National Medical Products Administration (NMPA) to conduct a Phase III clinical trial in adult patients with obesity complicated with knee osteoarthritis. HRS9531 is a novel dual agonist targeting both the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), representing a significant expansion of Hengrui&#039;s metabolic disease pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70176\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-17T13:43:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T13:43:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70176#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70176\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui&#8217;s HRS9531 Dual GIPR\\\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio\",\"datePublished\":\"2026-07-17T13:43:37+00:00\",\"dateModified\":\"2026-07-17T13:43:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70176\"},\"wordCount\":417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Hot targets\",\"Obesity\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70176#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70176\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70176\",\"name\":\"Hengrui's HRS9531 Dual GIPR\\\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-17T13:43:37+00:00\",\"dateModified\":\"2026-07-17T13:43:38+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has received approval from China's National Medical Products Administration (NMPA) to conduct a Phase III clinical trial in adult patients with obesity complicated with knee osteoarthritis. HRS9531 is a novel dual agonist targeting both the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), representing a significant expansion of Hengrui's metabolic disease pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70176#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70176\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70176#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui&#8217;s HRS9531 Dual GIPR\\\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's HRS9531 Dual GIPR\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has received approval from China's National Medical Products Administration (NMPA) to conduct a Phase III clinical trial in adult patients with obesity complicated with knee osteoarthritis. HRS9531 is a novel dual agonist targeting both the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), representing a significant expansion of Hengrui's metabolic disease pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70176","og_locale":"en_US","og_type":"article","og_title":"Hengrui's HRS9531 Dual GIPR\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has received approval from China's National Medical Products Administration (NMPA) to conduct a Phase III clinical trial in adult patients with obesity complicated with knee osteoarthritis. HRS9531 is a novel dual agonist targeting both the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), representing a significant expansion of Hengrui's metabolic disease pipeline.","og_url":"https:\/\/flcube.com\/?p=70176","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-17T13:43:37+00:00","article_modified_time":"2026-07-17T13:43:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70176#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70176"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui&#8217;s HRS9531 Dual GIPR\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio","datePublished":"2026-07-17T13:43:37+00:00","dateModified":"2026-07-17T13:43:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70176"},"wordCount":417,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","Hot targets","Obesity","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70176#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70176","url":"https:\/\/flcube.com\/?p=70176","name":"Hengrui's HRS9531 Dual GIPR\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-17T13:43:37+00:00","dateModified":"2026-07-17T13:43:38+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HRS9531 injection has received approval from China's National Medical Products Administration (NMPA) to conduct a Phase III clinical trial in adult patients with obesity complicated with knee osteoarthritis. HRS9531 is a novel dual agonist targeting both the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), representing a significant expansion of Hengrui's metabolic disease pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70176#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70176"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70176#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui&#8217;s HRS9531 Dual GIPR\/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70176"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70176\/revisions"}],"predecessor-version":[{"id":70178,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70176\/revisions\/70178"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}